A5029051704- Potassium and Related Disorders
- Electrolyte and hormonal disorders
- Peripheral Artery Disease Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Erythropoietin and Anemia Treatment
- Dialysis and Renal Disease Management
- Magnesium in Health and Disease
- Heart Failure Treatment and Management
- Iron Metabolism and Disorders
- Bipolar Disorder and Treatment
- Cerebrovascular and Carotid Artery Diseases
- Chronic Disease Management Strategies
- Membrane-based Ion Separation Techniques
- Patient Satisfaction in Healthcare
- Pharmaceutical Practices and Patient Outcomes
- Neurological Disorders and Treatments
- Hemoglobinopathies and Related Disorders
- Blood Pressure and Hypertension Studies
- Medication Adherence and Compliance
- Venous Thromboembolism Diagnosis and Management
- Neurological and metabolic disorders
- Vasculitis and related conditions
- Pharmacy and Medical Practices
- Parathyroid Disorders and Treatments
AstraZeneca (United Kingdom)
2017-2025
AstraZeneca (Brazil)
2024
AstraZeneca (Sweden)
2018-2024
To assess time trends in symptomatic peripheral artery disease (PAD) incidence and prevalence, secondary preventive therapy.Cohort study using The Health Improvement Network.UK primary care.Individuals aged 50-89 years identified annually between 2000 2014. Participants with PAD were Read codes.Incidence prevalence of from to 2014, overall by sex age. Proportion patients prescribed therapy acetylsalicylic acid (ASA), clopidogrel, an ACE inhibitor, angiotensin receptor blocker (ARB) and/or a...
This observational cohort study compared the likelihood of maintained (stabilized/up-titrated) renin-angiotensin-aldosterone system inhibitor (RAASi) therapy at 6 months following hyperkalaemia in patients with chronic kidney disease (CKD) and/or heart failure (HF) from USA, Japan and Spain who received sodium zirconium cyclosilicate (SZC) for least 120 days, relative to those no prescription a potassium (K+) binder. Using health registers hospital medical records, CKD HF receiving RAASi...
Few data are available on risk factors and associations with outcomes in symptomatic peripheral artery disease (PAD) populations primary care. We assessed characteristics cardiovascular patients those without UK care, quantified for disease. Among The Health Improvement Network (THIN) aged 50–89 years 2000–2010, a cohort (n = 28,484) matched comparison 113,940) were identified using Read codes. Cox proportional hazard ratios (HRs) 95% confidence intervals (CIs) calculated, adjusted potential...
Background Chronic kidney disease (CKD) is a major global health burden, and associated with increased adverse outcomes, poor quality of life, substantial care costs. While there an increasing need to build patient-centered pathways for improving CKD management in clinical care, data this field are scarce. Objective The aim study was understand patient-reported experiences, symptoms, treatment journeys among patients through retrospective qualitative approach based on available...
Objectives Traditional potassium (K + ) binders for treating hyperkalaemia are unpalatable and poorly tolerated. Newer K reportedly better tolerated; however, no published data describe their palatability, a determinant of long-term adherence. This study evaluated the palatability preference three binders: sodium calcium polystyrene sulfonate (S/CPS), zirconium cyclosilicate (SZC) patiromer sorbitex (patiromer). Design Phase 4, randomised, participant-blinded, cross-over study. Participants...
Abstract The purpose of this analysis was to assess potential predictors intra-cranial bleeding (ICB) and gastrointestinal (GIB) in patients with symptomatic peripheral artery disease (PAD) UK primary care. Patients PAD diagnosed from 2000 2010 were identified Health Improvement Network (THIN; N = 28,484). A nested case–control analysis, adjusted for confounders, performed calculate odds ratios (ORs) 95% confidence intervals (CIs) ICB or GIB. For GIB, follow-up restricted Hospital Episode...
We explored the association of anemia severity in patients with chronic kidney disease (CKD) and treatment work productivity China.Cross-sectional survey data from Chinese physicians their CKD were collected 2015. Physicians recorded demographics, characteristics, treatment. Patients completed Work Productivity Activity Impairment questionnaire. Data stratified by dialysis-dependence, hemoglobin (Hb) level, treatment.Based on 1,052 (704 non-dialysis-dependent [NDD] 348 dialysis-dependent...
ABSTRACT Background Individuals with chronic kidney disease (CKD) hospitalized hyperkalemia are at risk of recurrence and re-hospitalization. We present the rationale design CONTINUITY, a study to examine efficacy continuing sodium zirconium cyclosilicate (SZC)—an oral, highly selective potassium (K+) binder—compared standard care (SoC) on maintaining normokalemia reducing re-hospitalization resource utilization among participants CKD hyperkalemia. Methods This Phase 4, randomized,...
Abstract Background and Aims Guidelines recommend renin-angiotensin-aldosterone system inhibitor (RAASi) therapy at the maximum tolerated dose in patients with chronic kidney disease (CKD) and/or heart failure (HF). Hyperkalaemia (HK) may be a barrier to achieving guideline-directed targets, RAASi treatment often being down-titrated or discontinued who experience HK. suggest targeted anti-HK management potassium binders facilitate maintained RAASi. In CKD HF, we describe extent of HK-related...
Abstract Background and Aims Hyperkalaemia is a barrier to achieving guideline-directed renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. This observational cohort study compared the likelihood of maintained (stabilised or up-titrated) RAASi therapy at 6 months following an episode hyperkalaemia in patients with chronic kidney disease (CKD) from US Japan, who were treated sodium zirconium cyclosilicate (SZC) for least 120 days, relative those no potassium (K+) binder...
Background: Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy provides cardiorenal protection but is often down-titrated or discontinued following a hyperkalemia episode. This observational study describes the extent of hyperkalemia-related RAASi reduction in patients with chronic kidney disease (CKD) and/or heart failure (HF), and estimates number needed to treat (NNT) avoid first hospitalization if had been maintained at prior dose. Methods: Healthcare registers claims data...
<sec> <title>BACKGROUND</title> Chronic kidney disease (CKD) is a major global health burden, and associated with increased adverse outcomes, poor quality of life, substantial care costs. While there an increasing need to build patient-centered pathways for improving CKD management in clinical care, data this field are scarce. </sec> <title>OBJECTIVE</title> The aim study was understand patient-reported experiences, symptoms, treatment journeys among patients through retrospective...
Uncertainties regarding the ideal target for hemoglobin (Hb) and difficulties in management chronic kidney disease (CKD) patients may lead to variations anemia practice patterns. Using data from CKDOPPS clinics Brazil (BR), Germany (GE), United States (US) (2013-2018), we describe clinic-level targets Hb their associations with achieved levels advanced CKD receiving treatment.
Abstract BACKGROUND AND AIMS Individuals hospitalized with hyperkalaemia (HK) and chronic kidney disease (CKD) are at very high risk of HK recurrence, which often requires hospital re-admission [1]. Recurrent events have a significant impact on healthcare resource utilization (HCRU) costs [2]. Several approaches, such as reduction in dietary potassium (K+), or discontinuation diuretic renin-angiotensin-aldosterone system inhibitor (RAASi), oral K+ binders may be used to manage the outpatient...